Simplifying Complexity
Specificity
at scale.™
Sapient accelerates your discovery program through large scale identification of biomarkers.
A drug candidate with an associated biomarker is 2-10x more likely1 to obtain FDA approval. To date, however, the discovery of circulating biomarkers has been limited.
Sapient’s technology-based approaches break free from the limitations of traditional methods, enabling large scale measurement of thousands of circulating molecules to rapidly identify key biomarkers that inform drug development – including diagnostic biomarkers, pharmacodynamic biomarkers, drug efficacy biomarkers, and more.


EXPLORE THE APPLICATIONS
One platform — a wealth of actionable insights delivered.
-
Target Identification
Identify the best molecular biomarkers or new target candidates with activity that can be modulated by a therapeutic.
-
Early Disease Detection
Identify individuals at high risk for disease, years before onset, to develop drugs that more effectively limit disease progression.
-
Disease Progression
Reveal unique pathways essential to progressive disease and sub-stratify patients according to rapid progressors.
-
Assessment of Target Engagement
Confirm pharmacological engagement of key targets.
-
Patient Stratification / Companion Diagnostics
Identify patients most likely to benefit from a specific therapeutic intervention, and develop CLIA-certified diagnostic assays as a companion to therapies.
-
Safety Profiling
Predict adverse drug responses to obtain a more accurate view of potential drug safety issues, earlier in development.
-
Pharmacometrics and QSP
Uncover specific biomarkers for dosing and timing to maximize efficiency of drug therapies.
-
Clinical Trial Optimization
Reduce the size and accelerate the speed of trials by identifying patients most likely to respond positively to the drug.
-
Chemical Signatures of Disease
Identify new drug targets by uncovering biological drivers of disease.
-
Reagent Validation
Obtain accurate and rapid measurement of drug composition and purity.